Human testing: Sass and Needleman respond to industry. by Sass, Jennifer B & Needleman, Herbert L
Hazards of Fast Food 
In the article “Another Fast-Food Fear,”
Fields (2003) discussed the possible contami-
nants such as perfluorooctanoic acid (PFOA)
in cardboard containers used to serve fast
foods. The possible impurities, such as
PFOA, are not likely to be high-risk prod-
ucts because they are not ingested by the
consumers. It seems that the emphasis is mis-
placed. The real risk is the fried meat itself,
which contains heterocyclic amines. Hetero-
cyclic amines are documented mutagens and
carcinogens in animal models (Nagao and
Sugimura 2000; Weisburger 2002), and for
which there is human evidence not only of
several types of high-incidence cancers, such
as colon, breast, and prostate, but which also
affect the heart muscle (Butler et al.
2003). Documentation on these facts were
reported at the “8th International Conference
on Carcinogenic/Mutagenic N-Substituted
Aryl Compounds” (Snyderwine et al. 2002).
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Asbestos and International
Organizations
More information is available on the harmful
effects of asbestos, and more incontestable
epidemiologic and experimental evidence is
available on its carcinogenicity, than for any
other environmental agent. The first reports
of its use date back more than 2,000 years.
Herodotus and Plinium mention it
(Castleman 1986; McCulloch 1986; Selikoff
and Lee 1978). Despite early awareness of the
harmful effect of inhaled fibers, it was only in
1902, and only in the United Kingdom, that
asbestos was first included among the dusts
known to be harmful to humans (Selikoff
and Lee 1978). Cooke reported on fibrosis of
the lungs caused by asbestos inhalation in
1924, but the term “asbestosis” was first used
to describe it in 1927 (Cooke 1924, 1927).
In 1930, dust abatement was officially recog-
nized as the best way to eliminate the dam-
age caused by asbestos fibers (Merewether
and Price 1930); a few years later a detailed
study was conducted on the pathogenesis of
asbestosis (Mottura 1939). This awareness
notwithstanding, production and use of
asbestos continued and expanded undis-
turbed, with no measures being taken to pro-
tect exposed workers. 
A causal association with carcinoma of
the lungs was first reported in the 1930s in
the United States (Lynch and Smith 1935)
and in the United Kingdom (Gloyne
1935). In 1938 lung cancer was recognized
in Germany as an occupational disease of
workers who had been exposed to asbestos
(Nordman 1938). In 1942, again in
Germany, lung cancer associated with
asbestosis was recognized as a compensable
occupational disease (Proktor 1999).
Isolated case reports of tumors of the pleura
in people exposed to asbestos were pub-
lished in the 1930s and 1940s, and the
causal relationship between exposure to
asbestos and mesothelioma could have been
already established by the mid-1950s. The
final proof of a causal relationship is, how-
ever, generally attributed to Chris Wagner,
who in 1960 reported on 30 cases of histo-
logically confirmed mesotheliomas in min-
ers exposed to crocidolite (Wagner et al.
1960). In 1976, a working group convened
by the International Agency for Research
on Cancer (IARC) concluded that asbestos
in all its commercialized forms is carcino-
genic to humans and that no level of expo-
sure could be considered safe (IARC 1977).
In spite of the overwhelming evidence of
its carcinogenicity and of the enormous
amount of harm it has inflicted on miners,
workers in a variety of industrial sectors, and
members of the general population exposed
nonoccupationally, the use of asbestos is still
increasing in many parts of the world.
Under pressure to find solutions that satisfy
both health and safety as well as economic
concerns, economic considerations often
prevail, in particular in developing countries
where job opportunities are few and poverty
and unemployment are widespread (Harris
and Kahva 2003).
Ladou (2004) rightly points to the inade-
quacy of international organizations such as
the International Labour Office (ILO) and
the World Health Organization in address-
ing the worldwide problem that asbestos
poses for public health. These organizations
certainly are responsible for not having acted
earlier and more efficiently; however, part of
the reason for their inadequacy must be
sought elsewhere. There is a considerable gap
between the stated goals of these organiza-
tions, which are theoretically and demagogi-
cally supported by their founder states, and
what they actually can do. They were never
given the power such that their deliberations,
recommendations, and evaluations would
automatically be considered as the basis for
legislative measures. On the contrary, their
recommendations, typically those of the ILO
with regard to asbestos and aromatic amines,
have been blatantly disregarded by most
industrialized countries. Although they are
indisputably useful, international organiza-
tions are not supranational authorities that
can in all instances deliberate autonomously
and independently from the pressures exerted
by the individual countries that established
them. Several countries claim to support
public health–oriented initiatives fully, but
they do not favor programs that might have
a negative impact on short-sighted national-
istic interests or go against the lobbying of
powerful corporations. If this were not so,
how, as Ladou (2004) reminds us, could
many countries, conspicuously including
Canada and the Russian Federation, con-
tinue to produce and export asbestos? How
could many virtuous industrialized countries
export their risks, such as ship breaking, to
developing countries where the work is car-
ried out in poorly or unregulated conditions?
And how could asbestos-containing replace-
ment brake parts still be used in the United
States?
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Exceeding the Methyl Mercury
Reference Dose: How
Dangerous Is It? 
The methyl mercury exposure data presented
by Hightower and Moore (2003) with
regard to San Francisco fish consumers illus-
trates how regular consumption of certain
species of fish can lead to an exposure that
exceeds the current U.S. Environmental
Protection Agency (EPA) reference dose
(RfD). However, in spite of the impression
given by the cover headline “High Health
Cost of Eating Expensive Fish,” the study
sheds little light on the question of whether
the health of the authors’ patients was
affected by their methyl mercury exposure.
Hightower and Moore investigated the rela-
tionship between methyl mercury exposure,
fish consumption, and the U.S. EPA RfD—
not the relationship between methyl mercury
and health effects. 
Not all readers of EHP will appreciate
the difference between documenting expo-
sure levels and providing evidence for health
effects, and not every reader will have fol-
lowed the ongoing international controversy
over the health effects of methyl mercury for
fish consumers. The Science Selections pub-
lished in EHP can help to bridge these gaps
by providing clarification of important
issues and context.
Unfortunately, the Science Selection on
the Hightower and Moore article (Hood
2003) simply reinforced the impression left
by the authors that the methyl mercury
exposures in their patients were extraordinar-
ily and dangerously high and that such expo-
sure levels can result in symptoms of fatigue,
headache, decreased memory, and joint pain
in adults. In fact, methyl mercury exposures
many times higher than the U.S. EPA RfD
are common in fishing populations around
the world, and there has been little epidemi-
ologic investigation into the relationship
between exposure levels in fishing popula-
tions and these symptoms [Agency for Toxic
Substances and Disease Registry (ATSDR)
1999; National Research Council 2000].
The U.S. EPA RfD of 0.1 µg/kg body
weight/day is derived on the basis of the
health effects of prenatal exposure (U.S.
EPA 2001), as historically scientists
believed the developing fetus to be most
sensitive to methyl mercury. Two recent
large prospective epidemiologic studies in
fishing populations in the Seychelles (Myers
et al. 2003) and Faroe Islands (Grandjean
et al. 1997) have given mixed results, how-
ever, such that the question of neurologic
impairment in children of mothers who con-
sume large amounts of fish during pregnancy
remains open. With regard to adults, the epi-
demiologic evidence for adverse effects at the
exposure levels documented by Hightower
and Moore (2003) is even more uncertain. 
Because of this uncertainty, the deter-
mination of the appropriate level for the
methyl mercury RfD represents a subjective
policy decision, as well as a calculation
based on scientific data. The policy element
is most apparent in the choice of an uncer-
tainty factor, which sets the RfD many times
lower than the exposures that have been asso-
ciated with prenatal effects. Policy is also
reflected in the decision to apply one guide-
line to all members of the population. Many
scientists, physicians, and regulators con-
sider that, given current evidence, a guide-
line of 0.1 µg/kg body weight/day is too
low, particularly for men and older women. 
Regardless of whether one agrees with
the specific level set by the U.S. EPA for its
methyl mercury RfD (U.S. EPA 2001) in
the context of the agency’s mandate for
environmental protection, it is important
not to forget how this dose was determined
and its potential shortcomings as a dietary
guideline. The current RfD may be appro-
priate for Hightower and Moore’s patients,
who have a wide range of high-quality food
available to them. However, for many indi-
viduals, in the United States and around
the world, fishing remains an important
economic and cultural activity, and the
dietary alternatives to the fish they catch are
of much poorer nutritional value. For these
individuals, adhering to the U.S. EPA RfD
may not be the best advice.
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Methyl Mercury Reference
Dose: Response to Schoen
Mercury symptoms have been documented
in the literature from many different expo-
sures: from the “blue pill” used in the treat-
ment of syphilis (Hirschhorn et al. 2001), to
the mercurials used in teething powders caus-
ing acrodynia (or pink disease) (Dinehart
et al. 1988), the mercury nitrate in hatters
(O’Carroll et al. 1995), methyl mercury in
fish in Japan (Fukuda et al. 1999; Harada
1995), and methy mercury–tainted seed
grain in Iraq (Bakir et al. 1973). Goldsmiths,
tinsmiths, mirror makers, and miners also
had symptoms caused by occupational expo-
sure to mercury vapor (Ramazzini 1983).
Recently, contact lens solutions containing
ethyl mercury (thimerosal) caused blepharo-
conjunctivitis and punctate keratitis in many
contact lens wearers. As a result, thimerosal
was removed from the solutions (Campbell
et al. 1992). 
It is clear that the side effects of mercury
at lower exposure levels vary between indi-
viduals. This was evident in acrodynia, a
debilitating and sometimes deadly condition
of infants and children. Although the disease
was recognized as early as 1890, the cause—
multiple forms of mercury compounds—was
not confirmed until after 1948. It was later
thought to be a type of “hypersensitivity
reaction” because some children with the
same exposure were not noticeably affected
(Dinehart et al. 1988).
The variation of effects seen when com-
paring the Seychelles (Myers et al. 1995
2003) and Faroese (Grandjean et al. 1998)
cohorts may be simply because of genetic dif-
ferences. It is possible that an isolated popu-
lation exposed to mercury for generations
could, by natural selection, tolerate higher
amounts of mercury.
Recent articles have shown an associa-
tion with increased myocardial infarction
and death from myocardial infarction with
mercury levels close to the current reference
dose (RfD) set by the U.S. Environmental
Protection Agency (EPA) (Guallar et al.
2002; Rissanen et al. 2000; Salonen et al.
1995, 2000). Other researchers have identi-
fied an accumulation in the hearts of those
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thousands of times higher than even the
surrounding tissues of the same individual
(Frustaci et al. 1999). Induction of cardio-
myopathy in laboratory rats with mercury
exposure has also been demonstrated
(Bachmaier et al. 1999; Ilback et al. 1996,
2000; South et al. 2001).
In a recent article on carotid athero-
sclerosis, Salonen et al. (2000) concluded
that of 20 risk factors, mercury had the best
predictive value for intimal wall thickness
and was associated with progression of
carotid atherosclerosis. Cerebral arterio-
sclerosis was seen in infants suffering from
Minamata disease (Harada 1995).
A correlation between mercury and
autoimmune phenomena is of tremendous
concern. Mercury-induced autoimmunity is
one of the few animal models in which
administration of a chemical induces a spe-
cific loss of tolerance to self-antigens. Auto-
antibodies elicited include antiglomerular
basement membrane, anti–single-stranded
DNA, anti–double-stranded DNA, anti-
thyroglobulin, antiphospholipid, and anti-
collagen I and II (Bagenstose et al. 1999;
Bernier et al. 1995; Bigazzi 1994; Nielsen
and Hultman 2002; Stejskal et al. 1999;
Stejskal and Stejskal 1999; Via et al. 2003).
Although Minamata disease sufferers
were thought to have extremely high mer-
cury levels in hair, other studies in Japan
looked at lower-end chronic methyl mercury
exposures. Subjective complaints analyzed in
a population living in a methyl mercury–
polluted area showed an increase of symp-
toms after several years of exposure and had
atypical and subclinical features unlike those
of “classic Minamata.” Exposed individuals
reported higher prevalence of many com-
plaints than the internal and external con-
trols. Symptoms that were statistically
significant are as follows: muscle stiffness,
dysesthesia, hand tremor, dizziness, loss of
pain sensation, muscle cramps, upper arm
muscular atrophy, arthralgia, lumbago, leg
tremor, tinnitus, muscular atrophy, chest
pain, palpitations, fatigue, visual dimness,
and staggering. Symptoms with statistical
significance for men only were difficulty with
urination and thirst. Those with statistical
significance only in women were muscular
weakness, urine incontinence, forgetfulness,
and insomnia (Fukuda et al. 1999).
Adverse affects after low-level methyl
mercury exposure were reported recently in
the area of neuropsychiatric functioning in
adults (Yokoo et al. 2003). 
The U.S. EPA’s RfD was defined in the
Mercury Study Report to Congress as the
amount of methyl mercury that, when
ingested over a lifetime, is anticipated to
cause no adverse health effects to humans,
including those in sensitive populations (U.S.
EPA 1997). The dose is 0.1 µg/kg body
weight/day and corresponds to a blood level
of 4–5 µg/L or a hair level of 1.0 µg/g. The
benchmark dose lower limit is the intake of
methyl mercury associated with the lower
bound on a 95% confidence interval of a
dose producing a 5% prevalence of adverse
effects (in addition to a background effect of
5% adverse effects) (U.S. EPA 1997). The
benchmark dose lower limit calculated using
the Faroese study, which used fetal exposure
outcomes, was 58 µg/L [National Research
Council (NRC) 2000]. The NRC, through
review of a vast amount of literature, con-
cluded that the U.S. EPA’s RfD was justified
and recommended application of an uncer-
tainty factor of at least 10 in setting the U.S.
EPA’s RfD for methyl mercury (NRC 2000).
A benchmark dose for cardiac and
autoimmune disease has not been identified
and could be lower than that set for fetal
exposures. 
The best advice is still to consume no
more mercury than the RfD set by the U.S.
EPA to avoid accumulation over a lifetime.
Education for consumers and health-care
professionals can result in lower mercury
levels, despite high fish consumption.
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Arsenic in Food
Lasky et al. (2004) provided a notable contri-
bution to the evaluation of the public health
impacts of the use of arsenicals, among the
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Food and Drug Administration (FDA) for
administration in feed. To date, concerns
have focused on the association between the
use of these drugs and the prevalence of
drug-resistant pathogens in beef, poultry,
and pork products (Levy 2001). These con-
cerns have prompted the European Union
(EU) to ban the use of antimicrobial drugs
for nontherapeutic purposes in food animal
production (Sorum and L’Abee-Lund 2002),
and the FDA has initiated processes to stop
fluoroquinolone use in poultry and to reform
its procedures for evaluating new drug appli-
cations for use in food animals. 
There has been less concern, interna-
tionally or nationally, over the potential
public health risks associated with residues
of growth promoters in meat products,
although the discovery of chloramphenicol
in Asian shrimp in 2002 resulted in a
requirement that all shrimp be tested
before sale in the EU (Delegation of the
European Commission to Thailand 2002).
Arsenicals—arsanilic acid and roxarsone—
are permitted for nontherapeutic uses as
growth promoters in animal feeds in the
United States [National Research Council
(NRC) 1999]. Lasky et al. (2004) serve
notice that we must re-evaluate this use of
arsenicals not solely for environmental
impacts (Jackson et al. 2003) but also for
their role in human dietary exposures to
arsenic. It is noteworthy that most studies
of dietary sources of arsenic exposure do
not examine fresh poultry or pork products
(e.g., NRC 2000; Ryan et al. 2001).
However, in two respects, the conclu-
sions drawn by Lasky et al. (2004) probably
underestimate the true risks. First, as the
authors carefully noted, they had to estimate
the concentrations of arsenic in muscle using
the only U.S. Department of Agriculture
(USDA) data available, analyses of liver con-
centrations. It would be interesting to know
why the USDA does not analyze arsenic in
muscle, the tissue most commonly con-
sumed by humans. [In 1981, Westing et al.
(1981) reported higher levels of arsenic in
edible muscle tissue from cattle given feeds
containing poultry litter.] In the absence of
real data, Lasky et al. used information from
the drug manufacturer, Alpharma (Fort Lee,
NJ), which supported an inference of a
liver:muscle ratio of 2.9–11, depending on
withdrawal time before slaughter. However,
these assertions must be supported by data,
particularly because broiler chickens are fed
arsenicals throughout their lifespan. I was
unable to find any article on the toxico-
kinetics of arsenic in birds under controlled
conditions; however, following the guidance
of the World Health Organization/Food and
Agrigulture Organization (WHO/FAO)
Joint Expert Committee on Food Additives
(JECFA) 2000], I examined recent studies
on arsenic metabolism in mammals. Hughes
et al. (2003) reported that the body burden
of arsenic in mice under repeated-dose expo-
sure was significantly higher than that under
acute exposures; moreover, elimination of
arsenic after repeated doses was significantly
slower than after an acute dose. Under
repeated doses, the ratio of liver to muscle
arsenic changed dramatically over time, and
at day 17, arsenic in muscle was higher than
in liver. Thus, it is likely that the actual con-
centrations of arsenic in edible portions of
broiler poultry are higher than the estimates
of Lasky et al. (2004).
In addition, Lasky et al. (2004) referred to
a 20-year-old assessment of the human health
risks of ingesting arsenic (JECFA 1983).
Much more recently, in a risk assessment of
arsenic in drinking water, the NRC (2000,
2001) concluded that the excess cancer risks
associated with dietary exposures are consider-
ably greater than those previously assumed by
the WHO and other authorities. In its analy-
sis of cancer risks (NRC 2001), the commit-
tee concluded that exposure to 50 ppb arsenic
in drinking water could be associated with
excess cancer risks on the order of 1 in 100 (all
cancers). Exposure to 1.38–5.24 µg/kg/day As
from chicken consumption, as estimated by
Lasky et al. (2004), would be a significant
addition to drinking-water exposure based on
the NRC’s recommended maximum contami-
nation level (MCL) of 10 µg/L (~ 3 L/day, or
30 µg/day; for an adult weighing 70 kg, a
daily exposure of 0.43 µg/kg/day).
Surely it is time for the U.S. government
and international organizations to recon-
sider the acceptability of arsenic use in food-
animal production. Arsenic contributes to
the rise in drug resistance among pathogens
(Liu et al. 2001), and its use contaminates
the land when animal wastes are used as fer-
tilizers (Arai et al. 2003; Garbarino et al.
2003; Rutherford et al. 2003; Wing and
Wolf 2000). Also, direct consumer expo-
sures via food may well be a significant and
preventable portion of overall exposures to
this human carcinogen.
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Food and Population Growth
It was a pleasure to read “Infectious Disease:
The Human Cost of Our Environmental
Errors” by Weinhold (2004). His article on
microbes, people, and human environmental
errors has encouraged me to share new and
apparently unforeseen data that appear to
contradict popular and even scientific ideas
regarding human population dynamics.
Emerging scientific evidence indicates that
the absolute population numbers of species
on the planet increase primarily as a function
of food supply and also that microorganisms
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Correspondenceand human organisms have common
dynamics governing population.
Abundant research indicates that coun-
tries such as Australia, Canada, Italy, and
Tunisia, among many others, have shown a
declining trend in their rates of human
population growth (United Nations
Development Programme 2003). The geo-
graphically localized data need not blind us
to the fact that the global population is still
growing by the billions.
For too long, human population growth
has been widely viewed as somehow outside
the course of nature. The potential causes of
human population growth have seemed
complex, obscure, numerous, or even
unknowable, so that a strategy to address
the problem has been thought to be all but
impossible. One of the consequences of this
unnatural way of viewing human popula-
tion dynamics is that forecasts of global
population growth vary widely: Some fore-
casting data indicate the end to human
population growth soon, and other data
suggest skyrocketing numbers.
With recent correlation data from
Hopfenberg and Pimentel (2001) and the
current mathematical formulation of the
problem by Hopfenberg (2003), it may
now be possible for us to see human popu-
lation dynamics as a natural phenomenon.
Hopfenberg (2003) and Hopfenberg and
Pimentel (2001) provided an empirical pre-
sentation of a nonrecursive biological prob-
lem that is independent of ethical, social,
legal, religious, and cultural considerations.
This means that world human population
growth is a rapidly cycling positive-feedback
loop, a relationship between food and pop-
ulation in which food availability drives
population growth, and population growth
fuels the impression that food production
needs to be increased. The data indicate
that as we increase food production every
year, the number of people increases, too.
Perhaps a new biological understanding
is emerging with Hopfenberg’s research. It is
simply that the earth’s carrying capacity for
human organisms, like that for other organ-
isms, is determined by food availability. As
goes the food supply, so goes the popula-
tion. According to these data (Hopfenberg
2003; Hopfenberg and Pimentel 2001), sta-
bilization of food production at current lev-
els will lead to a stabilization of absolute
global human population numbers.
Redistribution of world food resources and
education for all children, in particular,
appear in the forseeable future. Socially and
culturally sanctioned humanitarian policies
and programs regarding the propagation of
our species will be developed and imple-
mented. Human population growth is a
huge problem, taking an ever-increasing toll
on the Earth’s resources; but we can take the
measure of this problem and find a remedy
that is consonant with universally shared
human values.
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Human Testing: Sass and
Needleman Respond to
Industry
In the March 2004 issue of EHP, we reported
on two examples of industry-sponsored stud-
ies that intentionally dosed human subjects
with toxic pesticides (Sass and Needleman
2004). The four industry-sponsored respon-
dents (Charnley and Patterson 2004; Chart et
al. 2004; McAllister 2004; Tobia et al. 2004)
focused primarily on their claims that the
studies were conducted in accordance with
formal ethical guidelines. Although that con-
tention is debatable, it misses fundamental
scientific criticisms we raised: a) sample sizes
and statistical power were too small to find an
effect, if one were present; b) study popula-
tions were inappropriate to establish no
observed effect levels (NOELs) for children,
the most sensitive population; c) outcome
measures were unsuitable to establish NOELs
for children; and d) study interpretations were
biased to ignore or dismiss evidence of adverse
health effects. The pesticides under considera-
tion were organophosphate neurotoxins that
are chemically related to military nerve gas. 
We would like to respond to Charnley
and Patterson (2004), Chart et al. (2004),
McAllister (2004), and Tobia et al. (2004)
in detail. 
First, if there is no chance of obtaining
valid conclusions, one cannot ethically expose
humans to risks. A recent National Research
Council (NRC) report (NRC 2004) stated
that underpowered studies “cannot be ethi-
cally acceptable if [they are] scientifically
invalid.” The industry human experimenta-
tion studies conducted to date employed
samples of < 60 subjects (AMVAC 1997;
Haines 1971; Wyld et al. 1992). The calcu-
lated statistical power to find an effect was
in the range of 0.2. This means that they
had a one-in-five chance of detecting an
effect if it were present, practically guaran-
teeing a finding of no effect. 
Second, the outcome measures in the
industry studies were peripheral red blood
cell acetyl cholinesterase (AChE) levels, a
symptom checklist, and blood pressure
(AMVAC 1997; Haines 1971; Wyld et al.
1992). The insensitivity of these measures
stands in contrast with recent literature on
low-dose noncholinergic toxic effects of the
organophosphate pesticides (OPs), includ-
ing effects on neurogenesis and behavior
(Aldridge et al. 2004; Icenogle et al. 2004;
Meyer et al. 2004a, 2004b). Although the
primary outcome of interest in protecting
children is the effect of OPs on the develop-
ing brain, neurobehavioral toxicity was not
evaluated in any of the industry reports
(AMVAC 1997; Haines 1971; Wyld et al.
1992). In addition, whereas evidence of car-
cinogenic properties has been published on
a number of OP pesticides, no attempt has
been made to evaluate this or any other
chronic end point.
Third, there was no urgent or com-
pelling need for human data, given the
existing evidence of toxicity from laboratory
experiments. Industry sought information
from human studies primarily to avoid the
10-fold safety factor when extrapolating
from animal studies to human risk.
Eliminating the safety factor would result in
setting higher levels of allowable exposure
and permit greater sales of the pesticides. 
Fourth, the AMVAC Chemical Corpora-
tion, sponsor of the dichlorvos (DDVP)
study we discussed (AMVAC 1997),
reported that although there were statistically
significant differences in cholinesterase inhi-
bition between treated and placebo groups,
“none of these differences were considered to
be of biological significance,” and the dose
was considered a NOEL. However, the U.S.
Environmental Protection Agency (EPA)
rejected AMVAC’s interpretation of the
results, instead concluding that “the reduc-
tion in RBC cholinesterase activity was con-
sidered by the Hazard ID [identification]
Committee to be biologically significant,”
and the dose tested was considered to be a
lowest observed effect level (LOEL) (U.S.
EPA 1998b). This illustrates our concern
that, “when studies are sponsored by chemi-
cal manufacturers with a financial interest in
the study outcome, the studies may be biased
in design and in interpretation” (Sass and
Needleman, 2004).
The responders from Bayer CropScience
(Tobia et al. 2004) stated that in our letter we
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sponsored aldicarb study on human subjects
had been reviewed and found “acceptable
and appropriate” by a U.S. EPA Scientific
Advisory Panel (SAP) in 1992 and reaffirmed
in 1998. In 1992 the SAP had no ethical
guidelines governing acceptance of human
studies. As to the 1998 review, the statement
by Tobia et al. (2004) is misleading. In fact,
the U.S. EPA statement issued in 1998 to the
SAP/Science Advisory Board (SAB) (U.S.
EPA 1998a) reads in its entirety:
[The U.S.] EPA is deeply concerned that some
pesticide manufacturers seem to be engaging in
health-effects studies on human subjects as a way
to avoid more protective results from animal tests
under the new Food Quality Protection Act. The
government has in place very stringent standards
that apply to federally funded research to ensure
the protection of human subjects. [The U.S.]
EPA will be asking its independent Science
Advisory Board to apply these same standards to
pesticide data submitted to [The U.S.] EPA by
companies for review. No human test data [have]
been used by [The U.S.] EPA for any final deci-
sions about acceptable levels of pesticide under
the new food safety law. The protection of public
health from adverse effects of pesticides can be
achieved through reliance on animal testing and
use of the highest ethical standards.
The U.S. EPA SAP/SAB members were in
strong agreement that neurotoxic agents
should be given to humans only if there was
an urgent and compelling need for the infor-
mation, and if there was no other way to
obtain it (U.S. EPA 2000).
There is growing literature on non-
cholinergic effects of organophosphates.
Meyer et al. (2004a) recently reported
developmental alterations in adenylyl
cyclase signaling in rat pups exposed to
chlorpyrifos, confirming neurodevelop-
mental effects through noncholinergic
mechanisms. Icenogle et al. (2004)
reported behavioral changes in adolescent
and adult rats after low-dose chlorpyrifos
administration. In humans, Berkowitz et al.
(2004) reported a small but significant
reduction in head circumference in infants
born to mothers with detectable levels of
chlorpyrifos in their blood, coupled with
low maternal paraoxonase (PON1) activity.
Perera et al. (2003) reported that chorpyri-
fos and diazinon found in mother’s blood
and umbilical cord blood was associated
with lower infant birth weight and length,
suggesting poorer predicted health out-
comes. In an update, Whyatt et al. (2004)
reported that regulatory restrictions on the
two pesticides measurably lowered exposure
and resulted in increased infant head size,
providing encouragement for strict regula-
tions to prevent or limit exposure. 
The regulation of pesticides must protect
against neurodevelopmental and neuro-
behavioral effects from even low-dose expo-
sures during critical stages in fetal and
neonatal development. Measures of cholines-
terase in adult peripheral blood are a poor
surrogate for these critical effects. The exam-
ples of industry-sponsored human tests of
pesticides are indefensible on both the scien-
tific and ethical grounds, and U.S. EPA
acceptance of such data for setting standards
opens the door to serious harm to the general
public as well as the subjects of such tests.
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CORRECTION
The November 2003 Forum article
“New Data on Methylmercury and
Fetuses” [EHP 111A753 (2003)]
incorrectly stated, “The hair mercury
of pregnant women in Minamata
ranged from 25 to 50 ppm.” In fact,
there are no direct data on the hair
mercury concentrations of the preg-
nant Minamata women whose chil-
dren had health problems associated
with methylmercury poisoning. EHP
regrets the error.